{"id":"W2031131661","doi":"10.1007/s12325-013-0060-1","title":"Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis","year":2013,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":520,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Sanofi; Genentech; AstraZeneca; Amgen; Pfizer; Allergan; Bristol-Myers Squibb; Genomic Health; GlaxoSmithKline","keywords":"Exemestane; Everolimus; Medicine; Hazard ratio; Internal medicine; Aromatase inhibitor; Breast cancer; Oncology; Clinical endpoint; Placebo; Population; Adverse effect; Progression-free survival; Confidence interval; Cancer; Clinical trial; Aromatase; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000928017,0.0002175447,0.0002670918,0.000115244,0.00004355888,0.00001947779,0.0002665832,0.0001383428,0.00004838455],"category_scores_gemma":[0.000007997705,0.0001534888,0.0000541005,0.0004574121,0.00008983387,0.00002877929,0.00005657515,0.0001594306,0.000004057934],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004645712,"about_ca_system_score_gemma":0.00006618691,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002028602,"about_ca_topic_score_gemma":0.0003067133,"domain_scores_codex":[0.9987189,0.00009442007,0.0002158241,0.0003874808,0.0002302955,0.0003530714],"domain_scores_gemma":[0.9993565,0.00001798216,0.0001046355,0.0003605525,0.00008496077,0.00007535975],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002194557,0.0004459274,0.8980334,0.00001239038,0.0003130155,0.00001686467,0.00008678866,0.002699363,0.01001219,0.00001727493,0.00005743412,0.08611077],"study_design_scores_gemma":[0.009300088,0.001864647,0.9804206,0.000080734,0.00005955249,0.000007265209,0.00006333051,0.0002918901,0.005825802,0.0001690802,0.001376064,0.000540919],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849027,0.01411797,0.00003588784,0.0001192263,0.0001078906,0.0004636488,0.00003006055,0.00001186867,0.0002107372],"genre_scores_gemma":[0.9913831,0.007716608,0.0003423076,0.0001147884,0.00005561861,0.0001705849,0.0001312979,0.0000244017,0.0000613203],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08556985,"threshold_uncertainty_score":0.625909,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.004021741589793851,"score_gpt":0.2567074031613948,"score_spread":0.252685661571601,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}